USTEKINUMAB: A GENETICALLY ENGINEERED BIOLOGIC FOR PSORIASIS TREATMENT – A CASE REPORT
Introduction: One of the critical challenges in modern dermatology is ensuring the effectiveness of treatment for patients with moderate-to-severe psoriasis. The introduction of genetically engineered biological therapies targeting specific pro-inflammatory cytokines has significantly advanced the management of this condition and improved patients' quality of life.
The aim of the study is to evaluate the clinical effectiveness of ustekinumab in a patient with severe psoriasis.
Materials and Methods: A retrospective case analysis was conducted using the medical records of a single patient who received inpatient treatment at the dermatovenereology department of City Hospital № 2, under the Abay Regional Health Authority. The patient's condition was monitored through the Comprehensive Medical Information System (CMIS) during the period from 2011 to 2024. Diagnostic and therapeutic procedures were performed in accordance with the approved clinical protocol of the Ministry of Health of the Republic of Kazakhstan № 172, dated October 14, 2022. The publication of treatment outcomes was authorized by the hospital administration and the patient through signed informed consent.
Results: After the addition of Stelara to standard anti-inflammatory therapy, the patient’s condition improved significantly. The drug alleviated symptoms such as skin itching, rashes, and joint pain. Clinical studies have demonstrated that ustekinumab effectively controls disease progression and enhances patients’ quality of life by reducing pro-inflammatory cytokines and modulating anti-inflammatory markers. Research has also confirmed its efficacy in treating psoriatic arthritis symptoms and its success across diverse populations, with 67.2% of patients achieving PASI75 after two doses.
Conclusion: This clinical case demonstrates the effectiveness of ustekinumab in treating moderate-to-severe psoriasis complicated by psoriatic arthritis. The improvement in skin lesions, joint symptoms, and overall patient condition highlights the potential of biological therapy in disease management and enhancing quality of life.
Number of Views: 27
Category of articles:
Clinical case
Bibliography link
Akhmetova A.K., Dyusseneva D.K., Kussainova A.A., Seidullaeva A.Zh., Kozhakhmetova D.K., Botabayeva A.S., Shamshudinov T.M., Zhokebaeva M.S., Petrova Yu.V., Kassym L.T. Ustekinumab: a genetically engineered biologic for Psoriasis treatment – a case report // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (6), pp. 211-218. doi 10.34689/SH.2024.26.6.023Related publications:
COMMUNITY-ACQUIRED PNEUMONIA IN PREGNANT. CLINICAL CASE.
A CASE OF AUTOIMMUNE COMPLICATIONS FOLLOWING COVID-19 VACCINATION WITH SINOVAC-CORONAVAC (CHINA)
EOSINOPHILIC GASTROINTESTINAL DISEASES IN CHILDREN. СLINICAL CASE.
USE OF A NEW DEVICE FOR DRAINAGE OF THE PLEURAL CAVITY IN CHILDREN
USTEKINUMAB: A GENETICALLY ENGINEERED BIOLOGIC FOR PSORIASIS TREATMENT – A CASE REPORT